

**ANTIBIOGRAM OF NASAL METHICILLIN RESISTANT *STAPHYLOCOCCUS AUREUS* (MRSA) FROM ANTENATAL CLINIC ATTENDEES IN A TERTIARY HOSPITAL, SOUTH-SOUTH NIGERIA**

C. A. Etok<sup>\*1</sup>, E. A. Ochang<sup>2</sup>, V. Inyang<sup>1</sup>, I. A. Onwuezobe<sup>2</sup>, E. E. Asuquo<sup>2</sup>

<sup>\*1</sup>Department of Microbiology, University of Uyo, Nigeria

<sup>2</sup>Department of Medical Microbiology and Parasitology, University of Uyo Teaching Hospital, Uyo, Nigeria.

---

**Abstract**

The antibiogram of nasal methicillin resistant *Staphylococcus aureus* (MRSA) from pregnant women attending University of Uyo Teaching Hospital was investigated using standard microbiological procedures. Out of 772 women, 180(23.3%) harboured nasal MRSA while 592 (76.7%) had MSSA (Methicillin Sensitive *Staphylococcus aureus*). The highest frequency (33.3%) occurred at week 16 while the lowest occurred at week 36 of the pregnancy period. Evaluation by logistic regression showed no risk factor involvement for MRSA. The patients were evaluated on their first visit (booking) therefore the MRSA were likely community-acquired. Antibiogram of isolates showed sensitivity mostly to clindamycin (80%), amoxicillin-clavulanic acid (76.7%), ceftriazone (69.4%) and resistance to co-trimoxazole (51.7%). The asymptomatic nasal colonisation of MRSA in pregnant women may therefore be a risk factor for serious systemic infection after delivery.

**Keywords:** MRSA, antibiogram, anterior nares, antenatal attendees

---

**1. Introduction**

Most staphylococci are resistant to penicillin due to the production of  $\beta$ -lactamase. A positive  $\beta$ -lactamase test indicates resistance to penicillin, ampicillin, amoxillin, azlocillin, carbenicillin, mezlocillin, piperacillin and ticacillin<sup>1</sup>. Resistance to the antistaphylococcal, penicillinase-stable penicillins (methicillin, nafcillin and oxacillin) has been referred to as "methicillin resistance".

Most resistance to oxacillin in staphylococci is mediated by the *mecA* gene which directs the production of a supplemental penicillin-binding protein, PBP2a in the cell wall of resistant strains<sup>2</sup>. MRSA appeared in 1961 shortly after the introduction of methicillin in clinical practice and its prevalence in US hospitals approached 50% in 2004<sup>3</sup>. MRSA has been shown to be one of the most common causes of nosocomial infections accounting for 40 to 70% of *S. aureus* infections in intensive care unit<sup>4</sup>. It also causes infections in neonatal intensive care unit<sup>5</sup>, among families as well as in pregnant and postpartum women<sup>6</sup>. Infection with MRSA is likely to be more severe and requires longer hospitalization<sup>7</sup>.

The study of nasal carriage of MRSA is important to the community since carriage plays a key role in the epidemiology and pathogenesis of Community Associated MRSA (CAMRSA). CAMRSA having the PVL gene is associated with skin infections like furuncles and with necrotizing pneumonia<sup>8</sup>.

The treatment options of MRSA are limited to few antibiotics like vancomycin, linezolid and teicoplanin. Since there are reports of reduced susceptibility and resistance of *S. aureus* to vancomycin from different countries especially Japan and USA<sup>9</sup>, the study was conducted to determine current prevalence of MRSA as well as antimicrobial susceptibility patterns of isolates from pregnant

women. This is because the presence of MRSA in anterior nares of these women could pose a pregnancy-related threat to both mother and neonate.

**2. Materials and Methods**

**2.1 Source of samples**

Swab specimens were obtained from antenatal attendees at the University of Uyo Teaching Hospital, Uyo. The hospital is a tertiary facility with 7,250 beds and serves as a referral centre. All the women consented to participation in the study and permission from the hospital authority was obtained.

**2.2 Collection of samples**

A swab specimen from the anterior nares was obtained from each pregnant woman involved in the study. Swabs were carefully inserted into each nostril so that the tip is entirely at the nasal osteum level (about 2.5 cm from the edge of the nares) and rolled gently 4 times.

**2.3 Culture procedures and isolation**

The swabs were immediately plated on blood agar and on mannitol-salt agar and incubated for 24 hours at 35°C. Mannitol fermenting colonies were subcultured and identified by morphology, microscopy and biochemical tests<sup>1</sup>.

**2.4 Screen test for MRSA**

A suspension equivalent to MacFarland 0.5 was prepared from each isolate. A swab was dipped and surface-plated on Mueller-Hinton agar. Thirty (30)  $\mu$ g oxacillin disk was placed on the medium and the plates incubated at 35°C for 24 hours. Plates with inhibition zones less than 12mm were considered methicillin resistant while those with zones greater than 13mm were susceptible.

**2.5 Antibiotic susceptibility test**

The Kirby-Bauer disk diffusion technique was adopted. Individual discs of the antibiotics were aseptically placed on Mueller-Hinton agar previously

seeded with 0.5 MacFarland suspension of each isolate. Plates were incubated at 37°C for 24 hours and zones of inhibition were recorded. All the MRSA isolates were used in the test.

#### 2.6 Inducible Macrolide Lincomycin Streptogramin B (iMLS<sub>B</sub>)

All isolates resistant to erythromycin but susceptible to clindamycin were subjected to iMLS<sub>B</sub> test. A 15µg erythromycin disc and 2µg clindamycin disc (Oxoid Ltd, Cambridge, UK) were placed 15-26mm apart on an already *S. aureus* seeded Mueller-Hinton agar plate. The plates were incubated for 18-24 hours at 35°C. Isolates that showed a flattening of the clindamycin zone of inhibition adjacent to the erythromycin disc (referred to as D-zone) were considered to exhibit inducible clindamycin resistance.

#### 2.7 Data analysis

Data were analysed using SPSS software involving regression and correlation.

### 3. Results

Figure 1 represents the distribution of MRSA and Methicillin Sensitive *Staphylococcus aureus* (MSSA) among antenatal attendees. Exactly 23.33% of the isolates were MRSA while 76.67% were MSSA.

Figure 2 shows the frequency of occurrence of MRSA with age. The highest frequency was obtained at age 31 years.

The frequency of occurrence of MRSA at different gestational ages is shown on Figure 3. The highest frequency (33.3%) occurred at week 16 while the lowest (3.3%) was at week 36 of the pregnancy period.

Table 1 shows the risk factors associated with MRSA colonisation in the attendees. Exactly 86.7% of the attendees were not previously admitted in the hospital, did not visit clinics and were not on any form of antimicrobials during the pregnancy period.

Table 2 shows the antibiotic susceptibility patterns of MRSA isolates. The isolates were mostly sensitive to clindamycin, amoxycillin-clavulanic acid and ceftriazone with susceptibilities of 80%, 76.7% and 69.4% respectively. The isolates were however resistant to cotrimoxazole.

Table 3 shows frequency of inducible macrolide streptogramin B. The MRSA isolates exhibited 31.1% resistance to erythromycin, 20% to clindamycin, 29.4% to ceftriazone, 35.6% to ciprofloxacin, 51.7% to sulfamethoxazole-trimetoprim and 22.2% to amoxillin-clavulanic acid.

### 4. Discussion

Methicillin resistant *S. aureus* has evolved as one of the most important causes of nosocomial infections worldwide. The data obtained from this study revealed that 23.33% antenatal women in the study area harboured MRSA in their anterior nares. However, 45% colonization by MRSA in health care workers was obtained in India<sup>10</sup>, while 36.2%

colonization by MRSA occurred in 9 Provinces in Iran<sup>11</sup>. Also, it was reported that 47% of all *S. aureus* isolates from US intensive care units in 1998 were methicillin-resistant<sup>12</sup>. The prevalence of MRSA among clinical specimens has been found to be 23.9%<sup>13</sup> and in other reports, the prevalence ranged from 20% to 32.8%<sup>14, 15</sup>. The prevalence of MRSA in some countries is still low. In the Netherlands for example, it is as low as 1%<sup>16</sup>. Thus the prevalence differ from one geographical location to another. Different epidemiological factors such as geographical and health system capability in running infection control programme influence the variability of prevalence of MRSA<sup>11</sup>.

There was negative correlation between gestational age (GA) and antimicrobial use (P=0.001) ie women at early GA are more likely to take antibiotics than those at a later GA age.

Although some reports show significantly increased rate of MRSA in elderly people<sup>17, 18</sup>, in this study, there was no significant difference between MRSA colonization and age. Apart from pregnancy, age is a risk factor because of its role in long term hospitalization, loss of immunity and longer antibiotic therapy<sup>19</sup>.

From the study, the MRSA isolates were community acquired because 86.7% of the attendees were not previously admitted in the hospital and 80% had no clinic visit history, therefore, no risk factor for colonisation by MRSA was noted.

Identifying the incidence of MRSA infections within the community would imply the existence of significant reservoirs of MRSA colonization within the community. It holds important implications for efforts to control the emergence of glycopeptide resistance among staphylococci. Recognising the emergence of CAMRSA might serve as a warning that MRSA control measures have failed<sup>12</sup>.

The importance of a dose-effect association, supporting a causal relationship between MRSA and antimicrobial drug use has been demonstrated<sup>20</sup>. However, in the study, 96.7% of attendees were not exposed to antimicrobial use.

In this study, the isolates were susceptible to clindamycin, amoxycillin-clavulanic acid and ceftriazone but resistant to cotrimoxazole (51.7%). A 100% resistance of MRSA to penicillin, co-amoxyclav and ampicillin and more than 70% resistance to cefotaxinic, erythromycin, ceftriazone and nalidixic acid has been reported<sup>11</sup>.

### 5. Conclusion

The MRSA isolates were community acquired and therefore no risk factor for colonisation was observed. Accurate and early detection of these strains in hospitals and community is encouraged. Also, a systematic review of isolation policies in the hospitals management of MRSA coupled with increased compliance with hand hygiene recommendation could lead to a significant reduction in MRSA.




Figure 1: The Distribution of MRSA and MSSA among antenatal attendees




Figure 2: Frequency of occurrence of MRSA with age




Figure 3: Frequency of occurrence of MRSA at different gestational ages

| Risk factor                  |                | Frequency | Percentage (%) |
|------------------------------|----------------|-----------|----------------|
| Previous Hospital Admissions | none           | 156       | 86.7           |
|                              | Last 3 months  | 18        | 10.0           |
|                              | Last 12 months | 6         | 3.3            |
| Clinic Visit                 | None           | 144       | 80             |
|                              | Last 3 months  | 24        | 13.3           |
|                              | Last 6 months  | 12        | 6.7            |
| Antimicrobial use history    | none           | 174       | 96.7           |
|                              | Last 3 months  | 6         | 3.3            |

Table 2: Susceptibility pattern of MRSA isolates

| Antibiotics                 | Frequency | Susceptibility (%) |
|-----------------------------|-----------|--------------------|
| Ciprofloxacin               | 114       | 63.3               |
| Cotrimoxazole               | 84        | 46.7               |
| Amoxycillin-clavulanic acid | 138       | 76.7               |
| Erythromycin                | 120       | 66.7               |
| Clindamycin                 | 144       | 80.0               |
| Ceftriazone                 | 125       | 69.4               |

Table 3: Frequency of Inducible Microlide streptogramin B

| Antibiotics                 | Frequency (R) | Percentage (%) |
|-----------------------------|---------------|----------------|
| Ciprofloxacin               | 64            | 35.6           |
| Cotrimoxazole               | 93            | 51.7           |
| Amoxycillin-clavulanic acid | 53            | 29.4           |
| Erythromycin                | 56            | 31.1           |
| Clindamycin                 | 36            | 20.0           |
| Ceftriazone                 | 53            | 29.4           |

## References

1. Clinical and Laboratory Standard Institute (CLSI) (2009). Performance standards for antimicrobial susceptibility testing; 16<sup>th</sup> informational supplement M100-S19. Vol 29 No 3. USA, Wayne. P.A.
2. El-Jahl, H. A, Jallad M and Thwaini, A. J (2008). Nasal carriage of methicillin resistance *Staphylococcus aureus* in individuals exposed and not exposed to hospital environment. *European Journal of Scientific Research*. 22(4): 570-574.
3. Mallorqui-Fernandez, G, Marreno, A, Garcia-Pique, S, Garcia-Castellanos, R, Xavier-Gomis and Ruth, F (2008). Staphylococcal methicillin resistance: fine focus on food and functions. *FEMS Microbiology letters*. 235: 1-8.
4. Mahmood, K, Tahir, T, Jameel, T, Ziauddin A and Aslan, H. F (2010). Incidence of methicillin resistant *Staphylococcus aureus* (MRSA) causing nosocomial infection in a tertiary care hospital. *ANNALS* 16(2): 91-94.
5. Healy, C. M, Hulten, K. G, Palazzi, D. L, Campbell, J. R and Baker, C. J (2004). Emergence of a new strain of methicillin resistant *Staphylococcus aureus* in neonatal intensive care unit. *Clinical infectious disease*. 39: 1460-1466.
6. Laibl, V. R, Sheffield, J. S, Roberts, S, McIntire, D, Trevino, A and Wendel, G. D (2006). Clinical preservation of community-acquired methicillin resistant *Staphylococcus aureus* in pregnancy. *Obstetrics & Gynecology*. 106: 461-465.
7. Madani, T, A, Al-Abdualla, A. A, Al-Sanousi, T. M, Ghabrah, S. Z, Afandi and Bajjunid, H. A (2001). Methicillin resistant *Staphylococcus aureus* in two tertiary care centres in Jeddah, Saudi Arabia. *Infectious Control Hospital Epidemiology*. 22: 211-216.
8. Vandenesch, F, Naimi, T, Enright, M. C, Lina, G, Nimmo, G. R, Heffernan, H, Liassine, N, Bes, M, Greenland, T, Reverdy, M and Etienne, J, (2003). Community-Acquired Methicillin-Resistant *Staphylococcus aureus* Carrying Panton-Valentine Leukocidin Genes: Worldwide Emergence. *Emerging infectious disease*. 9(8): 978-984.
9. Kleven, R. M, Morrison, M. A, Nadle, J, Petit, S, Gershman, K, Ray, S et al (2007). Invasive methicillin resistant *Staphylococcus aureus* infections in the United States. *JAMA*. 298 (15): 1763-1771.
10. Kumar, P, Shukla, I and Varshney, S (2011). Nasal screening of healthcare workers for nasal carriage of coagulase positive MRSA and prevalence of nasal colonization with *Staphylococcus aureus*. *Biology and medicine*. 3(2) special issue: 182-186.
11. Vaez, H, Alijan, T, Abdolvahab, M and Ezzat, A. G (2011). Evaluation of methicillin resistance *Staphylococcus aureus* isolated from patients in Golestan Province –North of Iran. *African Journal of microbiology research*. 5 (4): 432-436.
12. Jernigan, J (2000). The changing epidemiology of methicillin resistant *Staphylococcus aureus*. *Medicina*. 60 (suppl): 24-26.
13. Ahmad, S (2008). Methicillin resistance among clinical isolates of *Staphylococcus aureus* isolated at a Microbiology diagnostic centre in Kashmir, India. *Rawal Medical Journal*. 34: 1
14. Mehta, A. P, Rodrigues, C, Sheth, K, Jani, S, Itakimiyan, A, and Fazalbhoy (1998). Control of methicillin resistant *Staphylococcus aureus* in a tertiary care centre-A five year study. *Journal of Medical Microbiology* 16: 31-34.
15. Udaya, S, C, Harish, B, N, Umeshkumar, P. M and Navaneeth, B. V (1995). Prevalence of MRSA in JIPMER hospital-A prevalence report. *Indian Journal of Medical Microbiology* 15: 137-138
16. Lytkainen, O, Degener, J, E, Schrijnemakers, P, Bruisma, N et al, (2004). Methicillin resistant *Staphylococcus aureus* in Europe 1999-2002. *Emerging Infectious Diseases* 10: 1627-1634.
17. Fatholahzadeh, B, Emaneini, M, Gilbert, G, Udo, E, Aligholi, M and Modarressi, M. H (2008). Staphylococcal cassette chromosome mec (SCCmec) analysis and antimicrobial patterns of methicillin-resistant-*Staphylococcus aureus* (MRSA) isolates in Tehran, Iran. *Microbial Drug Resistance*. 14 (3): 217-222.
18. Hsueh, P. R, Teng, I. G, Chen, W, H, Pan A. J, Chen, M, I, Chang, S. C, Luh, K. T and Lin, F. U (2004). Increasing prevalence of methicillin resistant *Staphylococcus aureus* causing nosocomial infections at a University hospital in Taiwan from 1986-2001. *Antimicrobial agents Chemotherapy*. 48 (4): 1361-1364.
19. Waness, A (2010). Revisiting methicillin resistant *Staphylococcus aureus* infections. *Journal of Global infectious Disease*. 2(1): 49-56.
20. Salgado, C, D, Farr, B, M and Calfee, D, P (2003). Community-acquired methicillin resistant *Staphylococcus aureus*: a meta-analysis of prevalence and risk factors. *Clinical Infectious Diseases* 36: 131-139.